Kirkland Represents THL Partners on Majority Investment in Celerion

Kirkland & Ellis advised THL Partners, a premier private equity firm investing in middle market growth companies, on its majority investment in Celerion, a global leader in clinical pharmacology and bioanalytical sciences. The investment will support Celerion's continued growth and innovation, including expanding its clinical and bioanalytical capabilities and advancing its work to help pharmaceutical and biotechnology partners bring new therapies to patients worldwide. The transaction is expected to close in 2026, subject to customary closing conditions.

Read THL's press release

The Kirkland team included corporate lawyers Chris Elder, Jeremy Mandell, Ted Frankel, George Krug, Divya Gulati and Seffie Wilkinson; investment funds lawyers Nick Carreri and Derek Thomas; healthcare lawyers Dennis Williams, Brian King and Alexa Auger; tax lawyers Sehj Vather and Jeremy Miller; technology & IP transactions lawyers Dan Lewis, Kyla Risko and River Crane; employee benefits lawyers Matt Antinossi and Caitlin Bradford; executive compensation lawyers Mike Krasnovsky, Kelsie Harris and Cameron Bateman; employment & labor lawyers Risa Salins, Kayla Garcia and Olivia Hunter; real estate lawyers Rob Miceli, Henry Harper and Will Dunbar; environmental transactions lawyers Mike Saretsky and Jacob Manheim; antitrust & competition lawyers Matt Reilly, Stephanie Greco, Matthew Sinclair-Thomson, Matt Wheatley, Chris Thomas, Aleksandra Katolik and Marta Levytska; international trade & national security lawyers John Kabealo and Bryan Applefeld; and transactional liability lawyer Anna Geml.